Gracell Biotechnologies, Inc.
NASDAQ:
GRCL
Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors.
Key Facts
Auditor
Public Listing
Domicile
HQ/Management
Location of Key Operations
IR Contact
PricewaterhouseCoopers Zhong Tian LLP
IPO (January 7, 2021)
Cayman Islands
Suzhou, China
Gracie Tong, Internal
Analyst Coverage
Latest News
August 17, 2021: Gracell Biotechnologies Reports Second Quarter 2021 Unaudited Financial Results and Provides Corporate Update | Gracell Biotechnologies, Inc.
May 25, 2021: Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in June | Gracell Biotechnologies, Inc.
May 3, 2021: Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May | Gracell Biotechnologies, Inc.
April 23, 2021: Gracell Biotechnologies Announces Filing of Its Annual Report on Form 20-F for Fiscal Year 2020 | Gracell Biotechnologies, Inc.
April 6, 2021: Gracell Biotechnologies to Present at the 20th Annual Needham Virtual Healthcare Conference
March 17, 2021: Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day
March 9, 2021: Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update
February 23, 2021: Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021
January 19, 2021: Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL
January 15, 2021: Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products
January 8, 2021: Gracell Biotechnologies Announces Pricing of Initial Public Offering